The latest update is out from Boston Scientific ( (BSX) ).
On April 23, 2025, Boston Scientific announced the retirement of Dan Brennan, its Chief Financial Officer, after nearly 30 years with the company. Brennan will be succeeded by Jon Monson, currently the Senior Vice President of Investor Relations, effective June 30, 2025. Monson, with over 25 years at Boston Scientific, brings extensive financial expertise and will oversee several key company functions. This leadership transition is expected to ensure continuity and further strengthen the company’s financial strategies and operations.
Spark’s Take on BSX Stock
According to Spark, TipRanks’ AI Analyst, BSX is a Outperform.
Boston Scientific shows robust financial performance with strong revenue growth and effective cash management. Despite this, the stock’s technical indicators suggest a bearish trend, and its high P/E ratio indicates potential overvaluation. The positive sentiment from the earnings call and promising guidance for 2025 provide a positive outlook, but challenges such as pricing pressures in China and currency impacts remain concerns.
To see Spark’s full report on BSX stock, click here.
More about Boston Scientific
Boston Scientific is a global leader in medical technology, providing innovative solutions that improve patient health worldwide. With over 45 years in the industry, the company offers a wide range of devices and therapies for complex cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions.
YTD Price Performance: 6.34%
Average Trading Volume: 8,404,657
Technical Sentiment Signal: Sell
Current Market Cap: $140.6B
For detailed information about BSX stock, go to TipRanks’ Stock Analysis page.